Kiniksa Pharmaceuticals, Ltd.
Index- P/E8.35 EPS (ttm)2.00 Insider Own0.30% Shs Outstand69.44M Perf Week5.77%
Market Cap1.18B Forward P/E- EPS next Y-0.84 Insider Trans-19.18% Shs Float32.94M Perf Month34.44%
Income142.60M PEG- EPS next Q-0.22 Inst Own45.30% Short Float / Ratio8.47% / 7.87 Perf Quarter45.72%
Sales177.00M P/S6.66 EPS this Y11.80% Inst Trans-0.60% Short Interest2.79M Perf Half Y108.38%
Book/sh5.53 P/B3.01 EPS next Y-120.90% ROA50.30% Target Price22.20 Perf Year39.61%
Cash/sh2.84 P/C5.87 EPS next 5Y- ROE64.20% 52W Range7.36 - 17.19 Perf YTD41.63%
Dividend- P/FCF- EPS past 5Y-36.00% ROI-85.40% 52W High-3.05% Beta-0.22
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin88.70% 52W Low126.49% ATR0.88
Employees215 Current Ratio4.30 Sales Q/Q719.00% Oper. Margin-18.30% RSI (14)67.65 Volatility4.33% 6.17%
OptionableYes Debt/Eq0.00 EPS Q/Q814.00% Profit Margin80.50% Rel Volume0.72 Prev Close17.05
ShortableYes LT Debt/Eq0.00 EarningsNov 01 BMO Payout0.00% Avg Volume354.63K Price16.67
Recom1.60 SMA207.48% SMA5020.93% SMA20049.51% Volume256,089 Change-2.23%
Jun-29-20Reiterated BofA Securities Buy $25 → $40
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
Nov-30-22 04:01PM
Nov-23-22 04:01PM
Nov-10-22 09:40AM
Nov-07-22 09:55AM
09:15AM Loading…
Nov-01-22 09:15AM
Oct-31-22 04:01PM
Oct-24-22 09:40AM
Oct-05-22 08:50AM
Sep-21-22 12:00PM
Sep-20-22 10:30AM
Sep-12-22 08:30AM
Aug-22-22 09:55AM
Aug-05-22 09:55AM
09:09AM Loading…
Aug-04-22 09:09AM
Aug-03-22 04:01PM
Aug-02-22 04:01PM
Jul-22-22 12:00PM
Jun-22-22 09:14AM
Jun-19-22 09:49AM
May-05-22 06:52AM
May-03-22 09:15AM
May-02-22 04:01PM
Apr-13-22 09:08AM
09:15AM Loading…
Feb-22-22 09:15AM
Feb-18-22 04:01PM
Jan-10-22 08:00AM
Jan-03-22 04:01PM
Dec-31-21 10:00AM
Dec-29-21 09:37AM
Dec-28-21 07:40AM
Dec-01-21 10:00AM
Nov-23-21 04:01PM
Nov-19-21 10:18AM
Nov-04-21 11:38AM
Nov-03-21 10:33AM
Nov-01-21 09:15AM
Oct-29-21 04:01PM
Sep-21-21 04:01PM
Aug-16-21 08:00AM
Aug-03-21 09:15AM
Aug-02-21 04:01PM
Jul-26-21 03:00PM
Jul-20-21 04:01PM
Jun-08-21 04:01PM
Jun-01-21 04:01PM
May-10-21 05:49AM
May-04-21 08:00AM
Apr-12-21 07:30AM
Apr-01-21 08:00AM
Mar-19-21 10:55AM
Mar-18-21 04:30PM
Mar-04-21 08:12AM
Mar-02-21 08:00AM
Feb-28-21 10:54AM
Feb-23-21 08:00AM
Feb-17-21 04:15PM
Jan-27-21 09:36AM
Jan-11-21 08:00AM
Jan-04-21 04:20PM
Dec-22-20 08:00AM
Dec-18-20 08:51AM
Dec-15-20 08:00AM
Nov-30-20 08:00AM
Nov-24-20 08:00AM
Nov-23-20 08:00AM
Nov-17-20 08:00AM
Nov-16-20 08:00AM
Nov-10-20 09:15AM
Nov-09-20 04:01PM
Nov-05-20 07:30AM
Oct-29-20 08:00AM
Oct-26-20 08:00AM
Oct-14-20 09:54PM
Oct-07-20 10:14AM
Oct-06-20 08:00AM
Sep-24-20 04:12PM
Sep-21-20 08:00AM
Sep-15-20 08:00AM
Sep-09-20 04:01PM
Aug-31-20 08:00AM
Aug-04-20 08:00AM
Jul-30-20 07:30AM
Jul-28-20 03:42PM
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quart Barry DDirectorNov 29Option Exercise1.5921,95934,91521,959Dec 01 04:16 PM
Quart Barry DDirectorNov 29Sale16.1521,959354,6380Dec 01 04:16 PM
Paolini John F.CHIEF MEDICAL OFFICERNov 07Option Exercise1.8628,35752,74464,692Nov 09 04:16 PM
Paolini John F.CHIEF MEDICAL OFFICERNov 07Sale15.1828,357430,45936,335Nov 09 04:16 PM